• Skip to primary navigation
  • Skip to main content
  • Skip to primary sidebar
  • Skip to footer

MassDevice

The Medical Device Business Journal — Medical Device News & Articles | MassDevice

  • Latest News
    • Cardiovascular
    • Orthopedics
  • Wall Street Beat
    • Funding Roundup
    • Mergers & Acquisitions
  • Podcasts & Webinars
    • Podcasts
    • Webinars
  • Resources
    • About MassDevice
    • Newsletter Signup
    • Leadership in Medtech
    • Manufacturers & Suppliers Search
    • MedTech 100 Index
    • Videos
    • Whitepapers
  • DeviceTalks Tuesdays
  • Coronavirus: Live updates
Home » VasoTech gears up to go global

VasoTech gears up to go global

May 12, 2009 By Jim Montalto

It would have been easy for Tim Wu, cardiologist and founder of VasoTech Inc., to give up on his vision for the next generation of drug-eluting stent. He didn’t.

Instead, he invested $50,000 of his own money to set up shop in his garage and build a better stent, wrapping three state-of-the-art elements — a cobalt chromium stent, a biodegradable polymer and a potent combination of two anti-restenosis drugs — into a single device he calls the PowerStent. And he’s counting on that power to take his fledgling company global.

The next generation

The problem with the stents now used to treat blocked or narrowed coronary arteries, Wu explains, is their potential to cause clotting, known as thrombosis, and restenosis, a re-narrowing of the artery.

It’s not the tube-shaped stent itself, but the glue-like polymer that binds anti-thrombosis and anti-restenosis drugs to the stents he’d like to compete with that cause the problem, he says.

{IMAGELEFT:http://www.massdevice.com/sites/default/wp-content/uploads/headshots/VasoTech_stent_100.jpg}”My stent, which is made of cobalt chromium because it’s stronger and more flexible than metal or stainless steel, addresses this problem. The cobalt stents being used now contain a polymer that is not biodegradable,” Wu says.

He’s betting the PowerStent will catapult him to the top of the worldwide drug-eluting stent market. Besides its cobalt chromium structure, the device’s innovations involve a biodegradable polymer that holds two powerful anti-restenosis drugs.

The first, paclitaxel, also used in several of Boston Scientific’s drug-eluting stents, was originally aimed at combating tumor growth.

“But two drugs are key,” Wu explains. “I also use what Johnson & Johnson is using in its stents, an immuno-suppressive drug called sirolimus. Together, these drugs create a synergy that makes my stent more effective against restenosis.”

Wu claims his biodegradable materials also give him an edge over his competitors. Companies such as Singapore’s Biosensors International and India’s Sahajanand Medical Technologies use polylactide in their stents. But PLA can irritate arteries as it degrades and has yet to be cleared by the Food and Drug Administration for use in biodegradable stents.

“It causes pain similar to the pain you feel in your muscles after you work out,” Wu notes.

Instead of PLA, he uses PLGA or poly(lactic-co-glycolic acid), which is already in use in FDA-approved therapeutic devices because of its biodegradability and biocompatibility. When PLGA degrades, it produces acids the body can effectively metabolize without pain.

Dr. Donald Cutlip, who heads Beth Israel Deaconess Medical Center’s interventional cardiology program, says Wu might be onto something by focusing on polymers.

{IMAGELEFT:http://www.massdevice.com/sites/default/wp-content/uploads/headshots/Cutlip_Donald_100x100.jpg}”From an engineering standpoint, the polymer technology is the whole key here. The drug and stent are simple things, but the polymer is the key to success,” Cutlip says. “These drug-eluting stents are coated with a polymer on the outside and inside, and a certain drug is embedded within the polymer. The idea is to have the drugs released early and then keep going for about 30 days.”

The trick for folks like Wu, who hope to be the first to bring the next generation of stents to market, is determining exactly how long the devices need to persist in blood vessels to be most effective, Cutlip adds.

“There is a theory that a stent is only needed for a certain amount of time. This hasn’t been defined yet, but if a stent can stay in the artery for an ideal period of time to support the artery to heal, then you wouldn’t need the stent anymore. The stent could then dissolve and you wouldn’t have to worry about restenosis or clotting later on,” Cutlip explains.

Another trick lies in raising enough cash to shepherd a stent design through the rigors of the FDA approval process.

“The major problem with new drug-eluting stents, too, is the testing rigor that is appropriately required for FDA approval,” Cutlip notes. “It takes at least three to five years after a device is ready to enter trials before it can be considered for approval.”

Wu met the funding portion of the challenge in part through grants. VasoTech landed a $1.2 million Small Business Innovation Research grant from the National Institutes of Health last year, taking Wu out of his garage and into a 3,000-square-foot lab near Lowell’s historic mill district.

He then partnered with Harvard Medical School for clinical trials and teamed with the University of Massachusetts-Lowell’s Medical Device Development Center for additional funding and free lab space.

Now he’s seeking a half-million-dollar loan from the Massachusetts Life Sciences Center to develop a clean room to manufacture the device.

The road to China

As for the second, regulatory portion of the challenge, he’s pushing for domestic and international approval for the PowerStent, with a decided emphasis on the latter.

“There’s a huge market for cardiovascular devices,” he says. “The U.S. market is so hard right now, particularly with the current financial situation. It’s very hard to get investors to put money into this kind of technology.”

In the U.S., drug-eluting stents accounted for nearly 70 percent of the market last year, up from about 65 percent in 2007, at least according to Boston Scientific.

The worldwide coronary stent market was worth about $5 billion in 2007 and 2008, with drug-eluting stents accounting for about 80 percent of the total.

So Wu is turning to his homeland, where he sees enormous growth potential. China has more than 50 million coronary artery disease patients, he estimates, but very few receive angioplasties.

“I have the most advantage in the China market; it needs less money, about one-tenth the money in the U.S., and it’s relatively easy to get approval, only about three years to get China market approval,” he explains. “China is a huge market, but only about five percent of the patients get treated with this kind of technology, while in the U.S. it’s about 50 or 60 percent.”

China’s burgeoning middle class and steadily expanding prosperity could lead to a surge in the number of patients who receive the procedure.

“The Chinese market will continue to grow at 15 percent to 20 percent, which is why the potential is so huge. It’s the right time to jump in,” Wu says.

But before that can happen Wu needs to raise additional capital and complete clinical trials in Europe or China. If successful, he projects sales of $30 million to $50 million by 2011 in India and Europe.

“I’ll try to get a product over there and try to generate revenue from any local markets. Meanwhile, I’ll get more data for the FDA,” he explains, adding that he hopes to get FDA approval in 2012 or 2013.

He might be looking for success overseas, but Wu says he doesn’t plan on moving from Massachusetts any time soon.

{IMAGELEFT:http://www.massdevice.com/sites/default/wp-content/uploads/headshots/Wu_Tim_100x100.jpg}”There are so many advantages to being in Massachusetts; it’s a good base for medical devices. Whatever kind of material you need you can find locally and the government invests a huge amount in biotech,” he says.

And, as another Chinese strategic thinker put it, it’s wise to keep your friends close and your enemies closer. For Wu, they could be one and the same.

“I want to be the next Boston Scientific,” he says with a smile. “You never know. Twenty years ago, Boston Scientific was like me, just a couple of people. … If Boston Scientific likes me and they want to buy me, that’s OK. If no one buys me, I’ll just continue to develop.”

Filed Under: Business/Financial News

In case you missed it

  • Henry Schein hires former Medline veteran to drive ‘One Distribution’ push
  • FDA authorizes Labcorp’s non-prescription COVID-19 test that also detects flu, RSV
  • Massachusetts is competing for ARPA-H biomedical research center
  • Vivasure raises $23M initial Series D tranche; could reach up to $54M
  • Exactech announces breakthrough nod for JointMedica’s hip resurfacing system
  • Accuray names Sandeep Chalke as chief commercial officer
  • Labcorp launches at-home collection device for diabetes risk testing
  • Medtronic’s renal denervation system demonstrates better blood pressure control, time in range
  • iRhythm stays silent on federal grand jury subpoenas
  • Texas power grid struggles a year after cold stopped semiconductor plants
  • The road to a robot: Medtronic’s development process for its Hugo RAS system
  • How Dexcom’s portfolio goes beyond highly-anticipated next-gen G7
  • Zimmer Biomet appoints new chief accounting officer
  • Cook Medical makes next-gen in vitro fertilization incubator available in U.S., Canada
  • Boston Scientific co-founder Peter Nicholas is dead at 80
  • How Boston Scientific uses clinical feedback to advance innovation
  • How Stryker includes users for product design in the digital age

RSS From Medical Design & Outsourcing

  • The road to a robot: Medtronic’s development process for its Hugo RAS system
    Elephants are the perfect analogy for surgical robotics, Medtronic (NYSE:MDT) VP of Marketing for Surgical Robotics Mike Stow says. Speaking on the “Road to a robot: Designing technology to address unmet needs & barriers” panel at DeviceTalks Boston last week, Stow explained that elephants are big, taking up a lot of space and that they eat a lot, making… […]
  • iRhythm stays silent on federal grand jury subpoenas
    More than one year after receiving the first of two federal grand jury subpoenas seeking information about its products and communications with the FDA, iRhythm Technologies has said little publicly about the matter. It would have been easy to miss the San Francisco-based cardiac monitor maker’s initial disclosure last summer. iRhythm (Nasdaq:IRTC) was without a… […]
  • How Dexcom’s portfolio goes beyond highly-anticipated next-gen G7
    A lot of talk around Dexcom (Nasdaq:DXCM) in the last couple of years has centered around its next-generation G7 continuous glucose monitor. The latest iteration of the company’s CGM platform has already garnered CE mark this year and awaits FDA approval, with some expectations for that to come after the American Diabetes Association’s Scientific Sessions next month. The company also presented… […]
  • Texas power grid struggles in heat one year after record cold stopped semiconductor plants
    A heatwave in Texas took at least six power plants offline Friday, with high temperatures forecasted to blaze throughout this week. A record cold snap in February 2021 took NXP Semiconductors and Samsung chip fabrication facilities offline for weeks, contributing to a global semicondcutor shortage that is still throttling medical device production. There’s no indication… […]
  • How Stryker includes users for product design in the digital age
    Medical device developers and manufacturers like Stryker (NYSE:SYK) are changing how they approach design as digital technology becomes more crucial. Four Stryker executives shared how the Kalamazoo, Michigan–based orthopedic device giant is thinking differently about medical product development and how health care providers and patients will ultimately use them. The DeviceTalks Boston panel of Stryker… […]
  • DermaSensor wins MedTech Innovator Mid-Stage Companies Pitch Event
    DermaSensor Inc. — the creator of a handheld, point-and-click device to quickly assess skin lesions for cancer risk — is the winner of the MedTech Innovator Mid-Stage Companies Pitch Event.  The Miami-based mid-stage company beat out 1,000 applicants, more than 20 of which competed on-site May 10–11, 2022 at DeviceTalks Boston. DermaSensor walked away with… […]
  • Steris rises on Street-beating Q4, sets fiscal 2023 guidance
    Steris (NYSE:STE) shares ticked up today on fourth-quarter financial results that came in just ahead of the consensus forecast. The infection prevention technology company — headquartered in Dublin, Ireland, and run operationally out of Mentor, Ohio — posted profits of $52.3 million, or 52¢ per share, on sales of $1.2 billion for the three months… […]
  • Lucira Health asks FDA for EUA on molecular at-home COVID/flu test
    Lucira Health (Nasdaq: LHDX) today said it has asked the FDA for an emergency use authorization (EUA) for its combination COVID-19 and flu test. Emeryville, California–based Lucira said the at-home test would be available with a prescription to test for SARS-CoV-2, Influenza A and Influenza B. The Nucleic Acid Amplification Test (NAAT) platform has a… […]
  • Device commercialization platform AcuityMD raises $31M Series A to fund R&D engineer hiring
    AcuityMD said today it has raised $31 million in Series A funding for its medical device commercialization platform. “With our new funding, we plan to double down on R&D by growing our engineering team from 15 to over 40 over the next year,” AcuityMD co-founder and CEO Michael Monovoukas said in a blog post. “We’ll… […]
  • Rockley Photonics announces $81.5M private placement
    Rockley Photonics (NYSE:RKLY) announced today that it entered into agreements for an $81.5 million private placement. Participating investors agreed to purchase $81.5 million in convertible senior secured notes (due 2026) and warrants to purchase 26.5 million Rockley ordinary shares at an exercise price of $5 per share, subject to certain anti-dilution adjustments. Warrants purchased in… […]
  • Stryker leaders talk medtech trends at DeviceTalks Boston: ‘If you’re slow, you’re going to lose’
    The first day of DeviceTalks Boston closed with a panel of Stryker (NYSE:SYK) executives discussing new tools, technologies and strategies in medtech. Digital VP Tracy Robertson, Digital, Robotics, and Enabling Technologies President Robert Cohen and Surgical Technologies VP of Digital Innovation Siddarth Satish offered their thoughts on industry trends in healthcare and at the Kalamazoo,… […]

Leave a Reply

You must be logged in to post a comment.

Primary Sidebar

DeviceTalks Weekly

May 13, 2022
Our Pre-Post-DeviceTalks Boston episode, also MedtronicTalks replay with Gastro CMO Austin Chiang
See More >

MEDTECH 100 INDEX

Medtech 100 logo
Market Summary > Current Price
The MedTech 100 is a financial index calculated using the BIG100 companies covered in Medical Design and Outsourcing.
Need Medtech news in a minute?
We Deliver!

MassDevice Enewsletters get you caught up on all the mission critical news you need in med tech. Sign up today.

MDO ad

Footer

MASSDEVICE MEDICAL NETWORK

DeviceTalks
Drug Delivery Business News
Medical Design & Outsourcing
Medical Tubing + Extrusion
Drug Discovery & Development
Pharmaceutical Processing World
MedTech 100 Index
R&D World

Device Talks Webinars, Podcasts, & Discussions

Attend our Monthly Webinars
Listen to our Weekly Podcasts
Join our Device Talks Tuesdays Discussion

MASSDEVICE

Subscribe to MassDevice E-Newsletter
Advertise with us
About
Contact us
Add us on Facebook Follow us on Twitter Connect with us on LinkedIn Follow us on YouTube

Copyright © 2022 · WTWH Media LLC and its licensors. All rights reserved.
The material on this site may not be reproduced, distributed, transmitted, cached or otherwise used, except with the prior written permission of WTWH Media.

Advertise | Privacy Policy | RSS